Abstract
Matrix metalloproteinases (MMPs) are a family of 23 zinc-dependent proteases involved in extracellular matrix (ECM) remodeling and are implicated in diseases such as cancer, arthritis, and cardiovascular disorders. Broad-spectrum MMP inhibitors (MMPIs) have proven counterproductive due to the protective roles of certain MMPs and their expression in healthy tissues. Recent advances in protein engineering have enabled the development of highly specific protein-based MMPIs that precisely target individual MMPs. These engineered proteins, often derived from antibody fragments or endogenous MMPIs, offer enhanced selectivity, reduced off-target effects, and improved therapeutic efficacy. This review highlights novel strategies for the precise targeting of MMPs using engineered proteins and discusses their potential to transform diagnostics and treatment of MMP-driven diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 919-930 |
| Number of pages | 12 |
| Journal | Trends in Biochemical Sciences |
| Volume | 50 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2025 |
Bibliographical note
Publisher Copyright:© 2025 Elsevier Ltd
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antibodies
- matrix metalloproteinase inhibitors (MMPIs)
- matrix metalloproteinases (MMP)
- protein engineering
- protein-based therapeutics
- tissue inhibitors of matrix metalloproteinases (TIMPs)
Fingerprint
Dive into the research topics of 'Engineered protein inhibitors for precise targeting of matrix metalloproteinases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver